U.S. pharma giant copyright scrapped two experimental weight loss capsules past calendar year—a after-day-to-day capsule, lotiglipron, as a consequence of elevated liver enzymes in addition to a twice-every day pill, danuglipron, as a result of strong side effects—but CEO Albert Bour